Market Research Logo

Oncology Drug Discovery Services Market, 2017-2030

The early stages of research related to drug discovery, including the identification of a relevant target and a viable lead compound, play a crucial role in the overall success of a drug in preclinical and / or clinical studies. The process of drug discovery is extremely demanding, both in terms of capital expenses and time. Moreover, there is always a high risk of failure associated with R&D programs and, given the increasing regulatory stringency, the approval of new drugs has become significantly complex as well. Over the years, outsourcing has emerged as a popular trend in the pharmaceutical and biotechnology industry, and has demonstrated the potential to effectively cater to the growing demands associated with drug discovery as well. Contract Research Organizations (CROs), with dedicated teams of experts and innovative solutions across the various stages of the drug discovery and development process, are now located in all major global markets. Employing the services of these CROs offers a number of benefits to drug developers, including access to better technologies, latest R&D tools, cost and time savings and the potential to minimize risks associated with the drug discovery process.

Specifically, the oncology market, with an estimated global prevalence of 32 million, imposes a heavy burden on the healthcare system. There exists a significantly high unmet need for novel therapeutic options in this domain, translating into a growing demand for drug discovery initiatives. Therefore, CROs have now emerged as important stakeholders in the oncology market. The increasing trend towards outsourcing has triggered the establishment of several strategic collaborations between drug / therapy developers and CROs. In fact, several CROs have acquired other small / mid-sized CROs or collaborated with them for upgrading their own drug discovery capabilities in an effort to provide integrated services to its clients. Opportunities arising from the growth of personalized medicines, the vast unmet need for therapies for orphan indications, and the adoption of novel technology solutions, such as deep learning solutions, cloud-based technology platforms and 3D cell culture systems, are likely to act as some of the primary drivers of growth within this sector.

SCOPE OF THE REPORT
The “Oncology Drug Discovery Services Market, 2017-2030” report features an extensive study of the current market landscape and the future potential of CROs providing drug discovery services in oncology. Cancer, one of the leading causes of death worldwide, is an extremely complex disease and medical science is still struggling to figure out the various factors associated with the disease’s origin, propagation, spread (metastasis) and relapse. In fact, in 2017, a total of 1.7 million new cancer cases are estimated to be diagnosed in the US alone; during the same time period, close to 0.6 million patients are estimated to die due to cancer.

With the increasing complexity of drug discovery and development process, the overall spending on R&D in the pharmaceutical / biotechnology sector has increased over the past few years. According to one particular source, this spending has increased from USD 108 billion in 2006 to USD 145 billion in 2016. Heavy investments are being made towards the discovery of novel approaches for the treatment of various types of cancers. The industry is currently under tremendous pressure not only to meet the expectations of a growing patient population but also to identify ways to address the risks associated with novel drug discovery programs. Over the years, CROs offering drug discovery services have contributed significantly and have now grown to become an integral and indispensable part of the pharmaceutical and biotechnology industry.

This study presents an in-depth analysis of a diverse set of companies that offer services across the different steps, such as target identification, target validation, hit generation, hit-to-lead and lead optimization, of the drug discovery process. In addition to other elements, the report features:

A discussion on the current state of the market with respect to key players, along with information on the location of headquarters, drug discovery services provided (target identification, target validation, hit generation, hit-to-lead, lead optimization), depth of service portfolio (discovery / preclinical / clinical / commercial manufacturing) and product type (biologics / small molecules).

Elaborate profiles of established / emerging players. Each profile features a company overview, financial information, drug discovery service portfolio, recent developments and a view on its future outlook and strategy.

An overview of the most active regions in terms of drug discovery services for oncology. The report contains schematic representations of world maps that clearly indicate the location of drug discovery hubs across the world.

A comprehensive benchmark analysis, comparing the existing capabilities of various stakeholders within their respective peer groups, to identify ways to become more competitive in the industry. The analysis is based on key parameters such as the depth of service portfolio, the type of molecules researched and the nature of services offered by different companies.

An analysis of the agreements that have been established in the recent past, covering drug discovery agreements / research collaborations, license agreements, acquisitions, service alliances and joint venture agreements.

A competitive landscape review, featuring a multivariate bubble analysis, based on parameters such as the geographical location, founding year, number of drug discovery services offered and the level of partnering activity in recent years.

A discussion on the potential growth areas such as personalized medicines, orphan drugs and complex biopharmaceuticals, and innovative technologies including deep learning solutions and 3D cell culture systems, that are likely to present opportunities or act as growth drivers during the coming years.

In addition, the study features a detailed analysis of the existing market size and the future growth potential of the oncology drug discovery services market for the period 2017-2030. We have provided insights on the likely regional evolution of the market, across North America, Europe, China and the rest of the world. Additionally, we have provided informed estimates of the likely market evolution on the basis of type of product (small molecule, biologics) and key steps of drug discovery (target identification, target validation, hit generation, hit-to-lead and lead optimization). In order to account for the uncertainties associated with some of the key parameters, and to add robustness to our model, we have presented three different forecast scenarios, depicting the conservative, base and optimistic tracks of the market’s evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. For the purpose of this study, we invited over 100 stakeholders to participate in a survey, in order to solicit their opinions on upcoming opportunities, challenges and likely future trends. The opinions and insights presented in this study were also influenced by discussions conducted with experts in this field.

EXAMPLE HIGHLIGHTS
1. During our research, we identified over 115 companies that are actively involved in providing a wide array of oncology drug discovery services; hit-to-lead and lead optimization are amongst the most common services offered by these CROs.

2. Around 25% of the companies offer end-to-end services for drug discovery, starting from target identification till lead optimization. Examples of such one stop shops include (in alphabetical order) Charles River Laboratories, Evotec, GE Healthcare Life Sciences, GenScript, Lonza, PerkinElmer, Syngene, and TCG Lifesciences.

3. The current market is characterized by the presence of several established, as well as emerging CROs. Examples of established players with more than 25 years of overall experience in pharmaceutical sector include AMRI, Aurora Fine Chemicals, Cayman Chemical, ChemDiv, Dalton Pharma Services, DavosPharma, Organix, SRI Biosciences and Syncom. Some of the new players that have recently entered this domain include (in alphabetical order) Abzena, Aurelia Bioscience, Envigo, Enzymlogic, HitGen, INOVOTION, New England Discovery Partners and Tybema BioSolutions.

4. Over 80% of these CROs are located in Europe and North America. It is also worth highlighting that there are several players offering CRO services for oncology drug discovery in certain emerging regions within Asia Pacific, namely India and China. Examples of some of the large-sized CROs based in these locations include (in alphabetical order) Aurigene, GVK Biosciences, Pharmaron, Piramal Pharma Solutions, Sai Life Sciences, ChemPartner and WuXi AppTec.

5. Although the services offered by these companies range from early drug discovery to drug development and commercialization, there are several companies that solely focus on providing drug discovery services. These include (in alphabetical order) Aquila BioMedical, Aris Pharmaceuticals, Attana, Axxam, Beactica, BellBrook Labs, BioDiscovery Group, CanAm Bioresearch, CreaGen Biosciences, Domainex, Evotec, Exiris, Icagen, Organix, Sapient Discovery, Viva Biotech and Zobio.

6. The market has witnessed significant partnering activity in the past three years; several CROs have forged strategic alliances with other services providers in order to expand their drug discovery capabilities. We identified over 70 such collaborations, inked specifically for oncology research. Over 30% of the agreements signed by CROs with other players, including drug / therapy developers or academic players, were focused on co-conducting research for the discovery of either therapeutic targets or lead molecules. Such agreements also involved several big pharma giants, such as (in alphabetical order) AbbVie, AstraZeneca, Daiichi Sankyo, Debiopharm Group, MERCK and Sanofi. Recent examples of acquisitions that we came across include Villapharma’s acquisition by Eurofins (January 2017), HD Biosciences’ acquisition by Wuxi AppTec (January 2017), Cyprotex’s acquisition by Evotec (December 2016) and Blue Stream Laboratories’ acquisition by Charles River Laboratories (June 2016).

7. Driven by the rising demand for novel therapeutic targets and drugs, and the growing importance of contract services, we expect the market to continue on its growth trajectory in the foreseen future. We expect the oncology drug discovery services market to grow at an annualized rate of 6.2%, over the period 2017-2030. In terms of geography, majority (more than 70%) of the share is distributed between North America and Europe; other countries, such as China, are likely to grow at a relatively faster rate in the coming decade.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and type of biopharmaceuticals. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market till 2030. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 presents an executive summary of the insights captured in our research. It offers a high level view on the current state of the oncology drug discovery services market, specific factors impacting its growth and how the opportunity is likely to evolve in the mid-long term.

Chapter 3 provides an introduction to the drug discovery approach. It includes details on the time taken for a drug to traverse from the bench to the market, along with a historical account of the evolution of the drug discovery process. It also provides an in-depth explanation of each of the five steps involved in the drug discovery process, including details on associated methods / technologies / approaches. Further, the chapter features a discussion on the key challenges associated with conducting drug discovery research in-house, highlighting the need for contract services providers and the evident shift towards outsourcing drug discovery related operations in oncology.

Chapter 4 includes a comprehensive overview and analysis of the current market landscape of the oncology drug discovery services market. It features an analysis of drug discovery service providers on the basis of their geographical location, type of drug discovery service provided, depth of service portfolio (discovery / preclinical development / clinical development / commercial manufacturing) and the nature of product (small molecule / biologic).

Chapter 5 provides detailed profiles of some of the oncology drug discovery service providers that offer end-to-end services. Each profile features a brief overview of the company, financial information, insights on drug discovery related services offered by the company, recent developments and a comprehensive future outlook.

Chapter 6 provides detailed profiles of some of the oncology drug discovery service providers that offer target based services. Each profile features a brief overview of the company, its financial information, insights on drug discovery related services offered by the company, recent developments and a comprehensive future outlook.

Chapter 7 provides detailed profiles of some of the oncology drug discovery service providers that offer lead based services. Each profile features a brief overview of the company, its financial information, insights on drug discovery related services offered by the company, recent developments and a comprehensive future outlook.

Chapter 8 provides detailed profiles of some of the oncology drug discovery service providers that specialize in lead optimization. Each profile features presents a brief overview of the company, its financial information, insights on drug discovery related services offered by the company, recent developments and a comprehensive future outlook.

Chapter 9 provides a comprehensive market forecast, depicting how the drug discovery services market for oncology is likely to evolve till 2030. We have presented an analysis of the evolving financial opportunity across various regions, such as North America, Europe, China and ROW. Additionally, we have analyzed the market size based on the nature of molecule (biologic, small molecule) and the key steps of drug discovery (target identification, target validation, hit-to-lead, lead identification and lead optimization). It is worth mentioning that our projections are backed by credible data procured from both secondary and primary sources, and a robust forecast approach validated by in-house and external experts.

Chapter 10 provides a detailed benchmark analysis of the companies that provide drug discovery services in the oncology domain. The key parameters considered for this analysis include the depth of the service portfolio, the type of the molecule and the number of services offered by each company within a peer group (based on geography and employee base). The analysis allows the companies to compare their existing capabilities within their peer group and identify opportunities to become more competitive in the industry.

Chapter 11 features an elaborate discussion and analysis on the collaborations and partnerships that have been recently inked amongst players in this market. We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements in this segment of the overall market. In addition to the aforementioned analysis, the chapter offers an illustrative bubble analysis representing the competitive landscape of players involved in the space, based on their experience, number of drug discovery services offered and the level of activity in terms of collaborations established in the field of oncology research. The key objective of this analysis is to establish a region-wise understanding of contract services offerings and key players involved in the oncology drug discovery market globally.

Chapter 12 highlights important trends that are likely to impact CROs providing drug discovery services and influence their efforts to strengthen their presence in this competitive market. During our research, we identified a number of interesting trends, including focus on personalized medicines, orphan drugs and complex biopharmaceuticals, innovative applications of deep learning, use of 3 D cell culture systems and other novel technologies, which are being developed to reduce the innate complexities associated with drug discovery and optimize the time spent on the overall process. We believe that these trends are likely to significantly influence the industry’s evolution over the coming decade.

Chapter 13 presents insights from the survey conducted for this study. The participants, who were primarily Directors / CXO level representatives, helped us develop a deeper understanding on the nature of their services and their associated commercial potential.

Chapter 14 summarizes the overall report. It presents a list of key takeaways and offers our independent opinion on the current market scenario and key trends that are likely to determine how the market is likely to evolve in the mid- and long terms.

Chapter 15 is a collection of interview transcripts of the discussions held with some of the key players in this industry.

Chapters 16 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations that have been mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies and organizations have been mentioned in the report.
1. AbbVie
2. Abzena
3. Academic Medical Center Helsinki
4. Actelion Pharmaceuticals
5. ActivX Biosciences
6. Addex Therapeutics
7. Advinus Therapeutics
8. Agilux Laboratories
9. Agios Pharmaceuticals
10. Albany Molecular Research
11. AlphaGene
12. AmorChem
13. AnCoreX Therapeutics
14. Anthem Biosciences
15. APEIRON Biologics
16. Aptuit
17. Aquila BioMedical
18. Aragen Bioscience
19. Aris Pharmaceuticals
20. ArQule
21. Asahi Kasei Pharma
22. Asclepia MedChem Solutions
23. AsisChem
24. Astex Therapeutics
25. AstraZeneca
26. Attana
27. Aurelia Bioscience
28. Aurigene
29. Aurora Fine Chemicals
30. Avvinity
31. Axon Biochemicals
32. Axon Medchem
33. Axxam
34. Babraham Institute
35. Bayer Group
36. Beactica
37. BellBrook Labs
38. Beryllium Discovery
39. Bienta
40. Biobide
41. Biocon
42. BioDiscovery Group
43. BioDuro
44. BioFocus DPI
45. Biomedicum Genomics
46. BioMotiv
47. Bionaturis Group
48. Bionomics
49. BioNTech
50. BioStructures
51. Birkbeck College
52. Blue Stream Laboratories
53. British Columbia Cancer Agency
54. C4X Discovery
55. Cadiz University
56. California Institute for Biomedical Research
57. Caliper Life Sciences
58. CanAm Bioresearch
59. Cancer Research Technology
60. Cancer Research UK
61. Carrick Therapeutics
62. Cayman Chemical
63. Celgene
64. Celsis Group
65. Centauri Therapeutics
66. Centro Nacional de Investigaciones Oncológicas
67. Charles River Laboratories
68. Charnwood Molecular
69. ChemBridge
70. ChemDiv
71. ChemoGenics BioPharma
72. Chemveda Life Sciences
73. Child Health and Development Institute of Connection
74. Clininvent
75. CombinatoRx
76. Confluence Discovery Technologies
77. Covance
78. CreaGen Biosciences
79. CRELUX
80. CrownBio
81. Curadev Pharma
82. Curis
83. Cyprotex
84. Dabur Group
85. Dabur Research Foundation
86. Daiichi Sankyo
87. Dalton Pharma Services
88. Dana-Farber Cancer Institute
89. DavosPharma
90. Debiopharm Group
91. DIVERCHIM
92. Domainex
93. Dong-A ST
94. Dr. Reddy’s Laboratories
95. École Polytechnique Fédérale de Lausanne
96. EDELRIS
97. Enamine
98. Envigo
99. Enzymlogic
100. Epichem
101. Epistem
102. Eurofins Scientific
103. Evotec
104. Exiris
105. Exquiron Biotech
106. Exscientia
107. Fannin Innovation Studio
108. Felicitex Therapeutics
109. FORMA Therapeutics
110. Free University of Amsterdam
111. Fusion Antibodies
112. Galapagos
113. GalChimia
114. Galectin Therapeutics
115. GE Healthcare Life Sciences
116. Genentech
117. Genomics Medicine Ireland
118. GenScript
119. GL Chemtec International
120. GlaxoSmithKline
121. Griffith University
122. GVK Biosciences
123. H3 Biomedicine
124. Harlan Laboratories
125. HD Biosciences
126. Helmholtz Association
127. HitGen
128. Horizon Discovery
129. HQL Pharmaceuticals
130. Huntingdon Life Sciences
131. Icagen
132. iGEM
133. Infinity Pharmaceuticals
134. INOVOTION
135. Inserm
136. Insilico Medicine
137. Institut du cancer de Montréal
138. Institute for Research in Immunology and Cancer Commercialization of Research
139. Institute of Cancer Research, London
140. INTEGREX Research
141. IntelliSyn
142. IOTA Pharmaceuticals
143. Ipca Laboratories
144. Jagiellonian University
145. Janssen Biotech
146. Janssen Pharmaceuticals
147. Jinan Nornoon Biological Engineering
148. Johnson & Johnson
149. Joseph Fourier University
150. JPT Peptide Technologies
151. Jubilant Biosys
152. Jubilant Life Sciences
153. Juniper Pharma Services
154. Juno Therapeutics
155. KYORIN Pharmaceutical
156. LabCorp
157. Lead Discovery Center
158. Leiden University
159. Longthera Pharmaceuticals
160. Lonza
161. Marshall University
162. Mascot Industries
163. Max Planck Innovation
164. Max Planck Institute of Biochemistry
165. Medicilon
166. Medivir
167. Memorial Sloan Kettering Cancer Center
168. Mercachem
169. Merck Serono
170. Merck Sharpe & Dohme
171. Mir Lifescience
172. Mirimus
173. Moderna Therapeutics
174. n3D Biosciences
175. Nanjing Biotech Innovation Corporation
176. Nanjing Legend Biotechnology
177. Nanosyn
178. National Cancer Institute
179. National Resource Center for Mutant Mice
180. National University of Singapore
181. NEOMED Institute
182. New England Discovery Partners
183. Nile Scan & Labs
184. Nimbus Therapeutics
185. NovAliX
186. NuChem Therapeutics
187. OcellO
188. Oncompass Medicine
189. Oncotest
190. Oncotyrol
191. Ontario Institute for Cancer Research
192. Onyx Scientific
193. Organix
194. OriBase Pharma
195. Orion Corporation
196. OTAVAchemicals
197. OXELTIS
198. Oxford Bioscience Partners
199. Oxford University
200. Paraza Pharma
201. Paterson Institute for Cancer Research
202. Pepscan
203. PerkinElmer
204. Pfizer
205. Pharmaceutical Product Development
206. PharmAgra Labs
207. Pharmaron
208. Pharminox
209. PHENOMIN-ICS
210. Piramal Pharma Solutions
211. Prestwick Chemical
212. Proteros
213. Provid Pharmaceuticals
214. Queen’s University Belfast
215. Quotient Bioresearch
216. Qurient
217. Radboud University
218. Ratnamani Healthcare
219. Reach Separations
220. Red Glead Discovery
221. Redx Pharma
222. Regen BioPharma
223. Roche
224. RTI International
225. Sage Laboratories
226. Sai Life Sciences
227. SAMDI Tech
228. Sanofi
229. Sapient Discovery
230. SARomics Biostructures
231. SBH Sciences
232. Schrödinger
233. Selcia
234. Selvita
235. Semmelweis University
236. Shanghai ChemPartner
237. ShangPharma
238. Shionogi
239. SRI Biosciences
240. Stanford University
241. Sundia MediTech
242. Sygnature Discovery
243. Syncom Healthcare
244. Syngene
245. Synvolux Therapeutics
246. Taros Chemicals
247. TATA Group
248. Tata Trusts
249. TC Scientific
250. TCG Lifesciences
251. The Agency for Science, Technology and Research
252. The Eskitis Institute for Drug Discovery
253. The European Molecular Biology Laboratory
254. The Milner Therapeutics Institute
255. The Ohio State University Comprehensive Cancer Center
256. The Rockefeller University
257. The Scripps Research Institute
258. The University Medical Center Groningen
259. The University of Texas MD Anderson Cancer Center
260. The Wellcome Trust Sanger Institute
261. Thermo Fisher Scientific
262. Translational Drug Development
263. Translational Genomics Research Institute
264. Tri-Institutional Therapeutics Discovery Institute
265. Tybema BioSolutions
266. UbiQ
267. Ubiquigent
268. UCB Biopharma
269. United BioPharma
270. Univalor
271. University College London
272. University of California, Berkeley
273. University of Cambridge
274. University of Montreal
275. University of Strasbourg
276. University of Tsukuba
277. University of Wisconsin-Madison: School of Pharmacy
278. Vanta Bioscience
279. Vichem Chemie
280. Villapharma Research
281. ViroStatics
282. Viva Biotech
283. Wageningen University
284. Weill Cornell Medicine
285. WIL Research
286. WuXi AppTec
287. York University
288. Zenith Technologies
289. ZoBio


1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. Executive Summary
3. Introduction
3.1. Chapter Overview
3.2. Drug Discovery and Development Timeline
3.3. Drug Discovery Process: History and Evolution
3.4. Current Drug Discovery Process
3.5. Drug Discovery Process: Steps Involved
3.5.1 Target Identification: Introduction and Approaches
3.5.1.1. Chemical Proteomic Based Approaches
3.5.1.2. Expression Cloning Techniques
3.5.1.3. In Silico Approach
3.5.2. Target Validation: Introduction and Approaches
3.5.2.1. Pre-genomic Methods
3.5.2.2. Post-genomic Methods
3.5.3. Hit Discovery: Introduction and Approaches
3.5.4. Hit-to-Lead: Introduction and Approaches
3.5.5. Lead Optimization: Introduction and Models
3.6. Challenges Associated With In-House Drug Discovery
3.7. Shift in Trend towards Outsourcing of Drug Discovery Services
3.8. Oncology at the Forefront of Drug Discovery Research
4. Market Overview
4.1. Chapter Overview
4.2. Oncology Drug Discovery CROs: Overall Landscape
4.2.1. Oncology Drug Discovery CROs: Distribution by Geography
4.2.2. Oncology Drug Discovery CROs: Distribution by Type of Company
4.2.3. Oncology Drug Discovery CROs: Distribution by Type of Drug Discovery Step
4.2.4. Oncology Drug Discovery CROs: Distribution by Business Model
4.2.5. Oncology Drug Discovery CROs: Distribution by Depth of Service Portfolio
4.2.6. Oncology Drug Discovery CROs: Distribution by Nature of Molecule
5. CROs: End-to-End Service Providers
5.1. Chapter Overview
5.2. Charles River Laboratories
5.2.1. Company Overview
5.2.2. Key Operations
5.2.3. Financial Performance
5.2.4. Drug Discovery Services
5.2.5. Recent Developments and Future Outlook
5.3. Evotec
5.3.1. Company Overview
5.3.2. Key Operations
5.3.3. Financial Performance
5.3.4. Drug Discovery Services
5.3.5. Recent Developments and Future Outlook
5.4. GE Healthcare Life Sciences
5.4.1. Company Overview
5.4.2. Key Operations
5.4.3. Financial Performance
5.4.4. Drug Discovery Services
5.4.5. Recent Developments and Future Outlook
5.5. GenScript
5.5.1. Company Overview
5.5.2. Key Operations
5.5.3. Financial Performance
5.5.4. Drug Discovery Services
5.5.5. Recent Developments and Future Outlook
5.6. HD Biosciences (A Subsidiary of WuXi AppTec)
5.6.1. Company Overview
5.6.2. Key Operations
5.6.3. Drug Discovery Services
5.6.4. Recent Developments and Future Outlook
5.7. Vichem Chemie
5.7.1. Company Overview
5.7.2. Key Operations
5.7.3. Drug Discovery Services
5.7.4. Recent Developments and Future Outlook
6. CROs: Target Based Service Providers
6.1. Chapter Overview
6.2. Horizon Discovery
6.2.1. Company Overview
6.2.2. Key Operations
6.2.3. Financial Performance
6.2.4. Drug Discovery Services
6.2.5. Recent Developments and Future Outlook
6.3. Mir Lifescience (Division of MIR Group)
6.3.1. Company Overview
6.3.2. Key Operations
6.3.3. Drug Discovery Services
6.3.4. Recent Developments and Future Outlook
7. CROs: Hit / Lead Based Service Providers
7.1. Chapter Overview
7.2. DIVERCHIM
7.2.1. Company Overview
7.2.2. Key Operations
7.2.3. Drug Discovery Services
7.2.4. Recent Developments and Future Outlook
7.3. GVK Biosciences (A Business Division of GVK)
7.3.1. Company Overview
7.3.2. Key Operations
7.3.3. Financial Performance
7.3.4. Drug Discovery Services
7.3.5. Recent Developments and Future Outlook
7.4. NuChem Therapeutics
7.4.1. Company Overview
7.4.2. Key Operations
7.4.3. Drug Discovery Services
7.4.4. Recent Developments and Future Outlook
7.5. Prestwick Chemical (A Subsidiary of Bionomics)
7.5.1. Company Overview
7.5.2. Key Operations
7.5.3. Financial Performance
7.5.4. Drug Discovery Services
7.5.5. Recent Developments and Future Outlook
7.6. Syncom
7.6.1. Company Overview
7.6.1.1. Key Operations
7.6.2. Drug Discovery Services
7.6.3. Recent Developments and Future Outlook
8. CROs: Lead Optimization Service Providers
8.1. Chapter Overview
8.2. Envigo
8.2.1. Company Overview
8.2.2. Key Operations
8.2.3. Drug Discovery Services
8.2.4. Recent Developments and Future Outlook
8.3. Onyx Scientific (A Subsidiary of Ipca Laboratories)
8.3.1. Company Overview
8.3.2. Key Operations
8.3.3. Financial Performance
8.3.4. Drug Discovery Services
8.3.5. Recent Developments and Future Outlook
9. Market Sizing and Forecast
9.1. Chapter Overview
9.2. Forecast Methodology
9.3. Oncology Drug Discovery Services Market, 2017-2030 (USD Billion)
9.4. Oncology Drug Discovery Services Market, 2017-2030: Distribution by Region (USD Billion)
9.4.1. Oncology Drug Discovery Services Market: North America (USD Billion)
9.4.2. Oncology Drug Discovery Services Market: Europe (USD Billion)
9.4.3. Oncology Drug Discovery Services Market: China (USD Billion)
9.4.4. Oncology Drug Discovery Services Market: Rest of the World (USD Billion)
9.5. Oncology Drug Discovery Services Market, 2017-2030: Distribution by Nature of Molecule (USD Billion)
9.6. Oncology Drug Discovery Services Market, 2017-2030: Distribution by Type of Service (USD Billion)
10. Benchmark Analysis
10.1. Chapter Overview
10.2. Benchmark Analysis: Methodology
10.3. Benchmark Analysis: Peer Groups
10.3.1. Benchmark Analysis: North America, Peer Group I
10.3.2. Benchmark Analysis: North America, Peer Group II
10.3.3. Benchmark Analysis: North America, Peer Group III
10.3.4. Benchmark Analysis: Europe, Peer Group IV
10.3.5. Benchmark Analysis: Europe, Peer Group V
10.3.6. Benchmark Analysis: Asia Pacific, Peer Group VI
10.3.7. Benchmark Analysis: Asia Pacific, Peer Group VII
11. Recent Collaborations
11.1. Chapter Overview
11.2. Partnership Models
11.3. Oncology Drug Discovery Service Providers: Recent Collaborations
11.3.1. Oncology Drug Discovery Partnerships: Cumulative Trend, 2014 - H1 2017
11.3.2. Oncology Drug Discovery Partnerships: Distribution by Type of Partnership
11.3.3. Oncology Drug Discovery Partnerships: Most Active Players
11.3.4. Oncology Drug Discovery Partnerships: Analysis by Experience, Number of Services and Activity
12. Future Growth Opportunities
12.1. Chapter Overview
12.2. Oncology Drug Discovery is on the Cutting Edge of Personalized Medicine
12.3. Growing Popularity of Biologics Demands Specialized Research Expertise
12.4. Orphan Cancer Indications Offer New Opportunities for CROs
12.5. Start-ups in Oncology Will Continue to Seek Increased Support of CROs
12.6. Technological Advancements to Cater to Complexities Associated with the Drug Discovery Process
12.6.1. Deep Learning Technology
12.6.2. Organoids and 3D Cell Culture Systems
12.6.3. Acoustic Droplet Ejection (ADE) Technology
12.6.4. CRISPR–Cas9 Gene Editing Technology
12.6.5. Cloud Based Technology Platforms
13. Survey Analysis
13.1. Chapter Overview
13.2. Seniority Level of Respondents
13.3. Type of Drug Discovery Service
13.4. Nature of Molecule
13.5. Depth of Service Portfolio
13.6. Likely Market Size
13.7. Likely Growth Rate
14. Conclusion
14.1. Outsourcing has Emerged as a Convenient Option for Drug Discovery and Early Stage Development
14.2. Currently, Europe Stands out as the Major Hub for CROs, followed by North America and Asia Pacific
14.3. Lead Generation and Lead Optimization are the Most Frequently Outsourced Operations
14.4. Flexible Partnership Models have Fostered Collaborations between Drug Developers and CROs
14.5. Innovative Technologies and Untapped Opportunity Areas are Anticipated to Drive Long-Term Growth
14.6. Driven by the growing demand for contract services, the market is expected to witness continuous growth in the foreseen future
15. Interview Transcripts
16. Appendix 1: Tabulated Data
17. Appendix 2: List of Companies and Organizations
LIST OF FIGURES
Figure 3.1 Drug Discovery and Development Timeline
Figure 3.2 Drug Discovery Process: History and Evolution
Figure 3.3 Drug Target: Primary Criteria for Successful Identification
Figure 3.4 Drug Discovery Services: Advantages of Outsourcing
Figure 4.1 Oncology Drug Discovery CROs: Distribution by Geography
Figure 4.2 Oncology Drug Discovery CROs: Distribution by Country
Figure 4.3 Oncology Drug Discovery CROs: Distribution by Type of Company
Figure 4.4 Oncology Drug Discovery CROs: Distribution by Type of Drug Discovery Step
Figure 4.5 Oncology Drug Discovery CROs: Distribution by Business Model
Figure 4.6 Oncology Drug Discovery CROs: Distribution by Depth of Service Portfolio
Figure 4.7 Oncology Drug Discovery CROs: Distribution by Nature of Molecule
Figure 5.1 Charles River Laboratories: Business Segments
Figure 5.2 Charles River Laboratories: Key Operations
Figure 5.3 Charles River Laboratories: Revenues, 2012–2016 (USD Billion)
Figure 5.4 Charles River Laboratories: Revenues by Business Divisions, 2016 (USD Million)
Figure 5.5 Evotec: Key Operations
Figure 5.6 Evotec: Revenues, 2013–Q1 2017 (EUR Million)
Figure 5.7 Evotec: Revenues by Business Divisions, 2016 (EUR Million)
Figure 5.8 Evotec: Drug Discovery Services
Figure 5.9 GE Healthcare Life Sciences: Key Operations
Figure 5.10 GE Healthcare: Revenues, 2012–2016 (USD Billion)
Figure 5.11 GE Healthcare: Revenues by Business Divisions, 2016 (USD Billion)
Figure 5.12 GE Healthcare: Drug Discovery Technologies
Figure 5.13 GE Healthcare: Cancer Research Tools Used for Drug Discovery Steps
Figure 5.14 GenScript: Business Units
Figure 5.15 GenScript: Key Operations
Figure 5.16 GenScript: Revenues, 2012–2016 (USD Million)
Figure 5.17 GenScript: Revenues by Business Divisions, 2016 (USD Million)
Figure 5.18 GenScript: Drug Discovery Services
Figure 5.19 HD Biosciences: Key Operations
Figure 5.20 HD Biosciences: Drug Discovery Services
Figure 5.21 Vichem Chemie: Key Operations
Figure 6.1 Horizon Discovery: Key Operations
Figure 6.2 Horizon Discovery: Revenues, 2012–2016 (GBP Million)
Figure 6.3 Horizon Discovery: Revenues by Business Segments, 2016 (GBP Million)
Figure 6.4 Mir Lifescience: Key Operations
Figure 7.1 DIVERCHIM: Key Operations
Figure 7.2 DIVERCHIM: Drug Discovery Services
Figure 7.3 GVK Biosciences: Key Operations
Figure 7.4 GVK: Revenues, 2012–2016 (INR Billion)
Figure 7.5 NuChem Therapeutics: Key Operations
Figure 7.6 NuChem Therapeutics: Drug Discovery Services
Figure 7.7 Prestwick Chemical: Key Operations
Figure 7.8 Bionomics: Revenues, 2012–2016 (USD Million)
Figure 7.9 Syncom: Key Operations
Figure 8.1 Envigo: Key Operations
Figure 8.2 Onyx Scientific: Key Operations
Figure 8.3 Onyx Scientific: Revenues, 2013–2017 (INR Million)
Figure 9.1 Oncology Drug Discovery Services Market, 2017-2030: Base Scenario (USD Billion)
Figure 9.2 Oncology Drug Discovery Services Market, 2017, 2025 and 2030: Distribution by Region
Figure 9.3 Oncology Drug Discovery Services Market, 2017-2030: North America, Base Scenario (USD Billion)
Figure 9.4 Oncology Drug Discovery Services Market, 2017-2030: Europe, Base Scenario (USD Billion)
Figure 9.5 Oncology Drug Discovery Services Market, 2017-2030: China, Base Scenario (USD Billion)
Figure 9.6 Oncology Drug Discovery Services Market, 2017-2030: Rest of the World, Base Scenario (USD Billion)
Figure 9.7 Oncology Drug Discovery Services Market, 2017-2030: Distribution by Nature of Molecule, Base Scenario (USD Billion)
Figure 9.8 Oncology Drug Discovery Services Market, 2017-2030: Distribution by Type of Service, Base Scenario (USD Billion)
Figure 10.1 Benchmark Analysis: Distribution by Company Size (Number of Employees)
Figure 10.2 Benchmark Analysis: North America, Peer Group I
Figure 10.3 Benchmark Analysis: North America, Peer Group II
Figure 10.4 Benchmark Analysis: North America, Peer Group III
Figure 10.5 Benchmark Analysis: Europe, Peer Group IV
Figure 10.6 Benchmark Analysis: Europe, Peer Group V
Figure 10.7 Benchmark Analysis: Asia Pacific, Peer Group VI
Figure 10.8 Benchmark Analysis: Asia Pacific, Peer Group VII
Figure 11.1 Oncology Drug Discovery Partnerships: Cumulative Trend, 2014 – H1 2017
Figure 11.2 Oncology Drug Discovery Partnerships: Distribution by Type of Partnership
Figure 11.3 Oncology Drug Discovery Partnerships: Most Active Players
Figure 11.4 Oncology Drug Discovery Service Providers: 3-Dimensional Analysis based on Experience, Number of Services and Recent Collaborations (North America)
Figure 11.5 Oncology Drug Discovery Service Providers: 3-Dimensional Analysis based on Experience, Number of Services and Recent Collaborations (Europe)
Figure 11.6 Oncology Drug Discovery Service Providers: 3-Dimensional Analysis based on Experience, Number of Services and Recent Collaborations (Asia)
Figure 12.1 Oncology Drug Discovery Services: Future Growth Opportunities
Figure 13.1 Survey Analysis: Distribution by Geography
Figure 13.2 Survey Analysis: Seniority Levels of Respondents
Figure 13.3 Survey Analysis: Distribution by Type of Drug Discovery Service
Figure 13.4 Survey Analysis: Distribution by Nature of Molecule
Figure 13.5 Survey Analysis: Distribution by Depth of Service Portfolio
Figure 13.6 Survey Analysis: Likely Current Market Size
Figure 13.7 Survey Analysis: Likely Growth Rate
Figure 14.1 Oncology Drug Discovery Services Market, 2017, 2022 and 2030: Conservative, Base and Optimistic Scenarios (USD Billion)
LIST OF TABLES
Table 3.1 Drug Target Classification
Table 4.1 Oncology Drug Discovery Service Providers: Details on Geography and Type of Drug Discovery Service
Table 4.2 Oncology Drug Discovery Service Providers: Details on Type of CRO, Depth of Service Portfolio and Nature of Molecule
Table 5.1 Oncology Drug Discovery: End-to-End Service Providers
Table 6.1 Oncology Drug Discovery: Target Based Service Providers
Table 7.1 Oncology Drug Discovery: Hit / Lead Based Service Providers
Table 8.1 Oncology Drug Discovery: Lead Optimization Service Providers
Table 10.1 Benchmark Analysis: Peer Groups
Table 11.1 Oncology Drug Discovery Services: Recent Collaborations
Table 13.1 Survey Response: Overview of the Participating Companies
Table 13.2 Survey Response: Seniority Level of Respondents
Table 13.3 Survey Response: Type of Drug Discovery Service
Table 13.4 Survey Response: Nature of Molecule
Table 13.5 Survey Response: Depth of Service Portfolio
Table 13.6 Survey Response: Likely Current Market Size
Table 13.7 Survey Response: Likely Growth Rate
Table 16.1 Oncology Drug Discovery CROs: Distribution by Country
Table 16.2 Oncology Drug Discovery CROs: Distribution by Type of Company
Table 16.3 Oncology Drug Discovery CROs: Distribution by Type of Discovery Drug Step
Table 16.4 Oncology Drug Discovery CROs: Distribution by Business Model
Table 16.5 Oncology Drug Discovery CROs: Distribution by Depth of Service Portfolio
Table 16.6 Oncology Drug Discovery CROs: Distribution by Nature of Molecule
Table 16.7 Charles River Laboratories: Revenues, 2012–2016 (USD Billion)
Table 16.8 Charles River Laboratories: Revenues by Business Divisions, 2016 (USD Million)
Table 16.9 Evotec: Revenues, 2013–Q1 2017 (EUR Million)
Table 16.10 Evotec: Revenues by Business Divisions, 2016 (EUR Million)
Table 16.11 GE Healthcare: Revenues, 2012 – 2016 (USD Billion)
Table 16.12 GE Healthcare: Revenues by Business Divisions, 2016 (USD Billion)
Table 16.13 GenScript: Revenues, 2012 – 2016 (USD Million)
Table 16.14 GenScript: Revenues by Business Divisions, 2016 (USD Million)
Table 16.15 Horizon Discovery: Revenues, 2012 – 2016 (GBP Million)
Table 16.16 Horizon Discovery: Revenues by Business Segments, 2016 (GBP Million)
Table 16.17 GVK: Revenues, 2012–2016 (INR Billion)
Table 16.18 Bionomics: Revenues, 2012–2016 (USD Million)
Table 16.19 Onyx Scientific: Revenues, 2013–2017 (INR Million)
Table 16.20 Oncology Drug Discovery Services Market, 2017-2030: Conservative Scenario (USD Billion)
Table 16.21 Oncology Drug Discovery Services Market, 2017-2030: Base Scenario (USD Billion)
Table 16.22 Oncology Drug Discovery Services Market, 2017-2030: Optimistic Scenario (USD Billion)
Table 16.23 Oncology Drug Discovery Services Market, 2017, 2025 and 2030: Distribution by Region (%)
Table 16.24 Oncology Drug Discovery Services Market, 2017-2030: North America, Conservative Scenario (USD Billion)
Table 16.25 Oncology Drug Discovery Services Market, 2017-2030: North America, Base Scenario (USD Billion)
Table 16.26 Oncology Drug Discovery Services Market, 2017-2030: North America, Optimistic Scenario (USD Billion)
Table 16.27 Oncology Drug Discovery Services Market, 2017-2030: Europe, Conservative Scenario (USD Billion)
Table 16.28 Oncology Drug Discovery Services Market, 2017-2030: Europe, Base Scenario (USD Billion)
Table 16.29 Oncology Drug Discovery Services Market, 2017-2030: Europe, Optimistic Scenario (USD Billion)
Table 16.30 Oncology Drug Discovery Services Market, 2017-2030: China, Conservative Scenario (USD Billion)
Table 16.31 Oncology Drug Discovery Services Market, 2017-2030: China, Base Scenario (USD Billion)
Table 16.32 Oncology Drug Discovery Services Market, 2017-2030: China, Optimistic Scenario (USD Billion)
Table 16.33 Oncology Drug Discovery Services Market, 2017-2030: Rest of the World, Conservative Scenario (USD Billion)
Table 16.34 Oncology Drug Discovery Services Market, 2017-2030: Rest of the World, Base Scenario (USD Billion)
Table 16.35 Oncology Drug Discovery Services Market, 2017-2030: Rest of the World, Optimistic Scenario (USD Billion)
Table 16.36 Oncology Drug Discovery Services Market, 2017-2030: Distribution by Nature of Molecule, Conservative Scenario (USD Billion)
Table 16.37 Oncology Drug Discovery Services Market, 2017-2030: Distribution by Nature of Molecule, Base Scenario (USD Billion)
Table 16.38 Oncology Drug Discovery Services Market, 2017-2030: Distribution by Nature of Molecule, Optimistic Scenario (USD Billion)
Table 16.39 Oncology Drug Discovery Services Market, 2017-2030: Distribution by Type of Service, Conservative Scenario (USD Billion)
Table 16.40 Oncology Drug Discovery Services Market, 2017-2030: Distribution by Type of Service, Base Scenario (USD Billion)
Table 16.41 Oncology Drug Discovery Services Market, 2017-2030: Distribution by Type of Service, Optimistic Scenario (USD Billion)
Table 16.42 Benchmark Analysis: Distribution by Company Size (Number of Employees)
Table 16.43 Oncology Drug Discovery Partnerships: Cumulative Trends, 2014- H1 2017
Table 16.44 Oncology Drug Discovery Partnerships: Distribution by Type of Partnership
Table 16.45 Oncology Drug Discovery Partnerships: Most Active Players
Table 16.46 Survey Analysis: Distribution by Geography
Table 16.47 Survey Analysis: Seniority Levels of Respondents
Table 16.48 Survey Analysis: Distribution by Type of Drug Discovery Service
Table 16.49 Survey Analysis: Distribution by Nature of Molecule
Table 16.50 Survey Analysis: Distribution by Depth of Service Portfolio
Table 16.51 Survey Analysis: Likely Current Market Size
Table 16.52 Survey Analysis: Likely Growth Rate
Table 16.53 Oncology Drug Discovery Services Market, 2017, 2022 and 2030: Conservative, Base and Optimistic Scenarios (USD Billion)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report